ATE447625T1 - Zusammensetzungen und verfahren zur verwendung von fmoc-derivaten bei der dna-/rna-synthese - Google Patents
Zusammensetzungen und verfahren zur verwendung von fmoc-derivaten bei der dna-/rna-syntheseInfo
- Publication number
- ATE447625T1 ATE447625T1 AT03754749T AT03754749T ATE447625T1 AT E447625 T1 ATE447625 T1 AT E447625T1 AT 03754749 T AT03754749 T AT 03754749T AT 03754749 T AT03754749 T AT 03754749T AT E447625 T1 ATE447625 T1 AT E447625T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- fmoc
- dna
- compositions
- fmoc derivatives
- Prior art date
Links
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 230000006820 DNA synthesis Effects 0.000 title 1
- 230000006819 RNA synthesis Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000011152 fibreglass Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41406102P | 2002-09-27 | 2002-09-27 | |
| US10/670,015 US7534872B2 (en) | 2002-09-27 | 2003-09-24 | Compositions and methods for the use of FMOC derivatives in DNA/RNA synthesis |
| PCT/US2003/029465 WO2004029297A1 (en) | 2002-09-27 | 2003-09-25 | Compositions and methods for the use of fmoc derivatives in dna/ rna synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE447625T1 true ATE447625T1 (de) | 2009-11-15 |
Family
ID=32045270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03754749T ATE447625T1 (de) | 2002-09-27 | 2003-09-25 | Zusammensetzungen und verfahren zur verwendung von fmoc-derivaten bei der dna-/rna-synthese |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7534872B2 (de) |
| EP (1) | EP1546390B1 (de) |
| AT (1) | ATE447625T1 (de) |
| AU (1) | AU2003272561B2 (de) |
| CA (1) | CA2500285A1 (de) |
| DE (1) | DE60329925D1 (de) |
| WO (1) | WO2004029297A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5276118B2 (ja) * | 2008-01-22 | 2013-08-28 | カーディアック ペースメイカーズ， インコーポレイテッド | 患者の状態を評価するシステム |
| US8981076B2 (en) * | 2008-11-29 | 2015-03-17 | Chemgenes Corporation | Synthesis of N-FMOC protected deoxy nucleosides, ribo nucleosides, modified deoxy and ribo nucleosides, and phosphoramidites, and their use in oligonucleotide synthesis |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (de) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Manipulierte nukleinsäuren und anwendungsverfahren dafür |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US9481905B2 (en) * | 2013-02-19 | 2016-11-01 | Orizhan Bioscience Limited | Method of using neutrilized DNA (N-DNA) as surface probe for high throughput detection platform |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3041934A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimäre polynukleotide |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (de) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynukleotide zur codierung von low-density-lipoprotein-rezeptor |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015733A (en) * | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
| US5118800A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US4849513A (en) * | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6469158B1 (en) * | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| DE60024906T2 (de) * | 1999-03-05 | 2006-09-14 | Tosoh Corp., Shinnanyo | Eine am 3'-Ende modifizierte Nukleinsäuresonde, geeignet zur Hybridisierung und Detektion über Fluoreszenz |
| US6593466B1 (en) * | 1999-07-07 | 2003-07-15 | Isis Pharmaceuticals, Inc. | Guanidinium functionalized nucleotides and precursors thereof |
| US6958053B1 (en) * | 1999-11-24 | 2005-10-25 | Medrad, Inc. | Injector providing drive member advancement and engagement with syringe plunger, and method of connecting a syringe to an injector |
| WO2001041835A2 (en) * | 1999-12-07 | 2001-06-14 | Medrad, Inc. | Syringes, syringe tubing and fluid transfer systems |
| US6652489B2 (en) * | 2000-02-07 | 2003-11-25 | Medrad, Inc. | Front-loading medical injector and syringes, syringe interfaces, syringe adapters and syringe plungers for use therewith |
| AUPQ867900A0 (en) * | 2000-07-10 | 2000-08-03 | Medrad, Inc. | Medical injector system |
| US7018363B2 (en) * | 2001-01-18 | 2006-03-28 | Medrad, Inc. | Encoding and sensing of syringe information |
| US7553294B2 (en) * | 2002-05-30 | 2009-06-30 | Medrad, Inc. | Syringe plunger sensing mechanism for a medical injector |
| US7666169B2 (en) * | 2003-11-25 | 2010-02-23 | Medrad, Inc. | Syringe and syringe plungers for use with medical injectors |
-
2003
- 2003-09-24 US US10/670,015 patent/US7534872B2/en not_active Expired - Fee Related
- 2003-09-25 CA CA002500285A patent/CA2500285A1/en not_active Abandoned
- 2003-09-25 AT AT03754749T patent/ATE447625T1/de not_active IP Right Cessation
- 2003-09-25 WO PCT/US2003/029465 patent/WO2004029297A1/en not_active Ceased
- 2003-09-25 DE DE60329925T patent/DE60329925D1/de not_active Expired - Lifetime
- 2003-09-25 EP EP03754749A patent/EP1546390B1/de not_active Expired - Lifetime
- 2003-09-25 AU AU2003272561A patent/AU2003272561B2/en not_active Ceased
-
2007
- 2007-03-09 US US11/716,181 patent/US20070179289A1/en not_active Abandoned
-
2008
- 2008-03-19 US US12/051,784 patent/US7667033B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2500285A1 (en) | 2004-04-08 |
| AU2003272561B2 (en) | 2008-04-10 |
| US20040180355A1 (en) | 2004-09-16 |
| WO2004029297A1 (en) | 2004-04-08 |
| US7667033B2 (en) | 2010-02-23 |
| US20090171076A1 (en) | 2009-07-02 |
| DE60329925D1 (de) | 2009-12-17 |
| EP1546390B1 (de) | 2009-11-04 |
| US7534872B2 (en) | 2009-05-19 |
| EP1546390A1 (de) | 2005-06-29 |
| EP1546390A4 (de) | 2006-04-19 |
| AU2003272561A1 (en) | 2004-04-19 |
| US20070179289A1 (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60329925D1 (de) | Zusammensetzungen und verfahren zur verwendung von fmoc-derivaten bei der dna-/rna-synthese | |
| Ohgi et al. | A new RNA synthetic method with a 2 ‘-o-(2-cyanoethoxymethyl) protecting group | |
| Braich et al. | Regiospecific solid-phase synthesis of branched oligonucleotides. Effect of vicinal 2 ‘, 5 ‘-(or 2 ‘, 3 ‘-) and 3 ‘, 5 ‘-phosphodiester linkages on the formation of hairpin DNA | |
| RU2008128853A (ru) | Катионные олигонуклеотиды, автоматизированные способы их получения и их применение | |
| Praseuth et al. | Double helices with parallel strands are formed by nuclease-resistant oligo-[α]-deoxynucleotides and oligo-[α]-deoxynucleotides covalently linked to an intercalating agent with complementary oligo-[β]-deoxynucleotides | |
| ATE186327T1 (de) | Verfahren und zusammensetzungen für die stimulierung von knochenzellen | |
| DE602004030811D1 (de) | Multispezifische deimmunisierte cd3-bindende moleküle | |
| JP2005500025A5 (de) | ||
| JP2005517430A5 (de) | ||
| WO2004070007A3 (en) | Method for preparing single-stranded dna libraries | |
| Puah et al. | Selective binding to mRNA duplex regions by chemically modified peptide nucleic acids stimulates ribosomal frameshifting | |
| AU2003220115A1 (en) | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues | |
| Pon et al. | Rapid esterification of nucleosides to solid-phase supports for oligonucleotide synthesis using uronium and phosphonium coupling reagents | |
| JP2004501211A5 (de) | ||
| DE69815370D1 (de) | Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen | |
| CN109134541B (zh) | 长链生物素标记物及其制备方法和用途 | |
| WO2005067648A3 (en) | Multiplex spatial profiling of gene expression | |
| DE60222888D1 (de) | Echogene polymermikrokapseln und nanokapseln und verfahren zu ihrer herstellung und verwendung | |
| Pon et al. | Tandem oligonucleotide synthesis using linker phosphoramidites | |
| Slott et al. | MicroRNA Pools Synthesized Using Tandem Solid-Phase Oligonucleotide Synthesis | |
| JP6210484B2 (ja) | 鎖交換された二重鎖オリゴヌクレオチドの製造方法 | |
| CN101168774A (zh) | 实现dna序列分析中增加测序阅读长度的测定方法 | |
| US11466320B2 (en) | Multi-sequence capture system | |
| DE602004009849D1 (de) | Isochinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung um Melatonin System-Probleme zu behandeln | |
| ATE366818T1 (de) | Hirse-spezifische verzwergungsgene und verfahren ihrer anwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |